

This is a published notice on the Find a Tender service: <https://www.find-tender.service.gov.uk/Notice/008970-2023>

Tender

Provision of Haemophilia Advanced Therapy Medicinal Product (ATMP) Treatment Hubs

NHS England

F02: Contract notice

Notice identifier: 2023/S 000-008970

Procurement identifier (OCID): ocds-h6vhtk-03b6a8

Published 28 March 2023, 2:04pm

Section I: Contracting authority

I.1) Name and addresses

NHS England

1st Floor, Quarry House, Quarry Hill

Leeds

LS2 7UE

Contact

Josselin Canevet

Email

josselin.canevet@nhs.net

Country

United Kingdom

Region code

UKE - Yorkshire and the Humber

Internet address(es)

Main address

<https://www.england.nhs.uk/>

Buyer's address

<https://www.england.nhs.uk/>

I.3) Communication

The procurement documents are available for unrestricted and full direct access, free of charge, at

<https://health-family.force.com/s/Welcome>

Additional information can be obtained from the above-mentioned address

Tenders or requests to participate must be submitted electronically via

<https://health-family.force.com/s/Welcome>

Tenders or requests to participate must be submitted to the above-mentioned address

Electronic communication requires the use of tools and devices that are not generally available. Unrestricted and full direct access to these tools and devices is possible, free of charge, at

<https://health-family.force.com/s/Welcome>

I.4) Type of the contracting authority

Body governed by public law

I.5) Main activity

Health

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

Provision of Haemophilia Advanced Therapy Medicinal Product (ATMP) Treatment Hubs

Reference number

C153405

II.1.2) Main CPV code

- 85100000 - Health services

II.1.3) Type of contract

Services

II.1.4) Short description

NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of

NHS England (referred to as the Commissioner), is inviting suitably qualified and experienced providers to respond to this invitation to tender (ITT) exercise to commission haemophilia Advanced Therapy Medicinal Product (ATMP) treatment hubs.

The haemophilia ATMP treatment hub allocation model is as follows:

Lot 1 – One site to cover the NHS England population in the East of England

Lot 2 - Two sites to cover the NHS England population in London

Lot 3 – One site to cover the NHS England population in the Midlands

Lot 4 – One site to cover the NHS England population in the North East of England and Yorkshire

Lot 5 – One site to cover the NHS England population in the North West of England

Lot 6 – One site to cover the NHS England population in the South East of England

Lot 7 - One site to cover the NHS England population in the South West of England

Please note that providers must be located in the defined geographical catchment area(s) that they are interested in providing services to.

II.1.5) Estimated total value

Value excluding VAT: £1,000,000

II.1.6) Information about lots

This contract is divided into lots: Yes

Tenders may be submitted for one lot only

Maximum number of lots that may be awarded to one tenderer: 1

II.2) Description

II.2.1) Title

Lot 1 – One site to cover the NHS England population in the East of England

Lot No

1

II.2.2) Additional CPV code(s)

- 85100000 - Health services

II.2.3) Place of performance

NUTS codes

- UKH - East of England

II.2.4) Description of the procurement

The key objectives of the Procurement are to commission Haemophilia ATMP treatment hubs for patients with haemophilia types A and B to serve the population of England, and to

ensure that:

- the providers of Haemophilia ATMP treatment hubs have the correct qualifications and governance arrangements in place to provide these treatments for the NHS in England, and
- the Commissioner is offering services that are safe and of a high standard whilst fulfilling the Commissioner's public duty to provide services that are cost-effective.

The National Institute for Health and Care Excellence (NICE) will be assessing a number of

ATMPs for haemophilia A and B (see Appendix A). To meet the requirements of the expected

NICE guidance, NHS England is commissioning Haemophilia ATMP treatment hubs for patients with haemophilia types A and B. NHS England is seeking to commission eight of the

18 adult Comprehensive Care Centres (CCCs) in England to become 'haemophilia ATMP

treatment hubs'. These hubs will deliver the haemophilia gene therapy ATMPs approved by NICE with a contract duration of 8 years with the option to extend for up to a further 18 months.

For this ITT, we are only commissioning the Haemophilia ATMP treatment hubs.

Separately,

NHS England will work with the UKHCDO to develop a thorough care pathway detailing the responsibilities of both the hubs and spokes as well as referral and monitoring guidelines to manage the care of haemophilia patients undergoing ATMP treatment.

Given the significant amount of preparatory work that needs to be undertaken to deliver a gene therapy service, it is not feasible for commissioners and providers to wait until NICE has

made its recommendations to commence commissioning activity.

Providers are therefore submitting bids to deliver a service 'at risk': it may be the case that

the product does not receive a positive NICE recommendation.

Providers wishing to be considered for the delivery of these services will need to respond to

the provider selection documentation and submit responses prior to the deadline stated in this notice.

The ITT documentation including a questionnaire is available through the Atamis (Health Family) portal: <https://health-family.force.com/s/Welcome>. The reference is C153405 and the closing date for completed ITT responses is 12pm, midday on Friday 5th May 2023.

There will also be an opportunity to attend a market engagement event via Microsoft Teams

at 11.30am on Thursday 20th April 2023. If you would like to participate in this event, please

email josselin.canevet@nhs.net by 12pm on Tuesday 18th April 2023. All slides and questions and responses will be made available to all bidders following the event.

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) Estimated value

Value excluding VAT: £1,000,000

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Start date

16 December 2023

End date

15 December 2031

This contract is subject to renewal

No

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: Yes

Description of options

As a result of this procurement exercise an agreement will be established with the successful

Bidders for a period of 8 years with the Commissioner having the option to extend the Contract for up to a further 18 months. It is anticipated that the contract start date will be 16th December 2023 which is 90 days following the expected final NICE guidance; however, this may be subject to change.

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

Lot 2 - Two sites to cover the NHS England population in London

Lot No

2

II.2.2) Additional CPV code(s)

- 85100000 - Health services

II.2.3) Place of performance

NUTS codes

- UKI - London

II.2.4) Description of the procurement

The key objectives of the Procurement are to commission Haemophilia ATMP treatment hubs for patients with haemophilia types A and B to serve the population of England, and to

ensure that:

- the providers of Haemophilia ATMP treatment hubs have the correct qualifications and governance arrangements in place to provide these treatments for the NHS in England, and
- the Commissioner is offering services that are safe and of a high standard whilst fulfilling the Commissioner's public duty to provide services that are cost-effective.

The National Institute for Health and Care Excellence (NICE) will be assessing a number of

ATMPs for haemophilia A and B (see Appendix A). To meet the requirements of the expected

NICE guidance, NHS England is commissioning Haemophilia ATMP treatment hubs for patients with haemophilia types A and B. NHS England is seeking to commission eight of the

18 adult Comprehensive Care Centres (CCCs) in England to become 'haemophilia ATMP treatment hubs'. These hubs will deliver the haemophilia gene therapy ATMPs approved by

NICE with a contract duration of 8 years with the option to extend for up to a further 18 months.

For this ITT, we are only commissioning the Haemophilia ATMP treatment hubs.

Separately,

NHS England will work with the UKHCDO to develop a thorough care pathway detailing the

responsibilities of both the hubs and spokes as well as referral and monitoring guidelines to

manage the care of haemophilia patients undergoing ATMP treatment.

Given the significant amount of preparatory work that needs to be undertaken to deliver a gene therapy service, it is not feasible for commissioners and providers to wait until NICE has

made its recommendations to commence commissioning activity.

Providers are therefore submitting bids to deliver a service 'at risk': it may be the case that

the product does not receive a positive NICE recommendation.

Providers wishing to be considered for the delivery of these services will need to respond to the provider selection documentation and submit responses prior to the deadline stated in this notice.

The ITT documentation including a questionnaire is available through the Atamis (Health Family) portal: <https://health-family.force.com/s/Welcome>. The reference is C153405 and the closing date for completed ITT responses is 12pm, midday on Friday 5th May 2023.

There will also be an opportunity to attend a market engagement event via Microsoft Teams

at 11.30am on Thursday 20th April 2023. If you would like to participate in this event, please

email josselin.canevet@nhs.net by 12pm on Tuesday 18th April 2023. All slides and questions and responses will be made available to all bidders following the event.

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) Estimated value

Value excluding VAT: £1,000,000

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Start date

16 December 2023

End date

15 December 2031

This contract is subject to renewal

No

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: Yes

Description of options

As a result of this procurement exercise an agreement will be established with the successful

Bidders for a period of 8 years with the Commissioner having the option to extend the Contract for up to a further 18 months. It is anticipated that the contract start date will be 16th December 2023 which is 90 days following the expected final NICE guidance; however, this may be subject to change.

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

Lot 3 – One site to cover the NHS England population in the Midlands

Lot No

3

II.2.2) Additional CPV code(s)

- 85100000 - Health services

II.2.3) Place of performance

NUTS codes

- UKF - East Midlands (England)

II.2.4) Description of the procurement

The key objectives of the Procurement are to commission Haemophilia ATMP treatment hubs for patients with haemophilia types A and B to serve the population of England, and to

ensure that:

- the providers of Haemophilia ATMP treatment hubs have the correct qualifications and governance arrangements in place to provide these treatments for the NHS in England, and
- the Commissioner is offering services that are safe and of a high standard whilst fulfilling the Commissioner's public duty to provide services that are cost-effective.

The National Institute for Health and Care Excellence (NICE) will be assessing a number of ATMPs for haemophilia A and B (see Appendix A). To meet the requirements of the expected NICE guidance, NHS England is commissioning Haemophilia ATMP treatment hubs for patients with haemophilia types A and B. NHS England is seeking to commission eight of the 18 adult Comprehensive Care Centres (CCCs) in England to become 'haemophilia ATMP treatment hubs'. These hubs will deliver the haemophilia gene therapy ATMPs approved by NICE with a contract duration of 8 years with the option to extend for up to a further 18 months.

For this ITT, we are only commissioning the Haemophilia ATMP treatment hubs. Separately, NHS England will work with the UKHCDO to develop a thorough care pathway detailing the responsibilities of both the hubs and spokes as well as referral and monitoring guidelines to manage the care of haemophilia patients undergoing ATMP treatment.

Given the significant amount of preparatory work that needs to be undertaken to deliver a gene therapy service, it is not feasible for commissioners and providers to wait until NICE has made its recommendations to commence commissioning activity. Providers are therefore submitting bids to deliver a service 'at risk': it may be the case that the product does not receive a positive NICE recommendation. Providers wishing to be considered for the delivery of these services will need to respond to the provider selection documentation and submit responses prior to the deadline stated in this notice.

The ITT documentation including a questionnaire is available through the Atamis (Health Family) portal: <https://health-family.force.com/s/Welcome>. The reference is C153405 and the closing date for completed ITT responses is 12pm, midday on Friday 5th May 2023. There will also be an opportunity to attend a market engagement event via Microsoft Teams at 11.30am on Thursday 20th April 2023. If you would like to participate in this event, please email josselin.canevet@nhs.net by 12pm on Tuesday 18th April 2023. All slides and questions and responses will be made available to all bidders following the event.

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) Estimated value

Value excluding VAT: £1,000,000

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Start date

16 December 2023

End date

15 December 2031

This contract is subject to renewal

No

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: Yes

Description of options

As a result of this procurement exercise an agreement will be established with the successful

Bidders for a period of 8 years with the Commissioner having the option to extend the Contract for up to a further 18 months. It is anticipated that the contract start date will be 16th December 2023 which is 90 days following the expected final NICE guidance; however, this may be subject to change.

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

Lot 4 – One site to cover the NHS England population in the North East of England

Lot No

4

II.2.2) Additional CPV code(s)

- 85100000 - Health services

II.2.3) Place of performance

NUTS codes

- UKC - North East (England)

II.2.4) Description of the procurement

The key objectives of the Procurement are to commission Haemophilia ATMP treatment hubs for patients with haemophilia types A and B to serve the population of England, and to

ensure that:

- the providers of Haemophilia ATMP treatment hubs have the correct qualifications and governance arrangements in place to provide these treatments for the NHS in England, and
- the Commissioner is offering services that are safe and of a high standard whilst fulfilling the Commissioner's public duty to provide services that are cost-effective.

The National Institute for Health and Care Excellence (NICE) will be assessing a number of

ATMPs for haemophilia A and B (see Appendix A). To meet the requirements of the expected

NICE guidance, NHS England is commissioning Haemophilia ATMP treatment hubs for patients with haemophilia types A and B. NHS England is seeking to commission eight of the

18 adult Comprehensive Care Centres (CCCs) in England to become 'haemophilia ATMP treatment hubs'. These hubs will deliver the haemophilia gene therapy ATMPs approved by

NICE with a contract duration of 8 years with the option to extend for up to a further 18 months.

For this ITT, we are only commissioning the Haemophilia ATMP treatment hubs.

Separately,

NHS England will work with the UKHCDO to develop a thorough care pathway detailing the

responsibilities of both the hubs and spokes as well as referral and monitoring guidelines to

manage the care of haemophilia patients undergoing ATMP treatment. Given the significant amount of preparatory work that needs to be undertaken to deliver a gene therapy service, it is not feasible for commissioners and providers to wait until NICE has made its recommendations to commence commissioning activity. Providers are therefore submitting bids to deliver a service 'at risk': it may be the case that the product does not receive a positive NICE recommendation. Providers wishing to be considered for the delivery of these services will need to respond to the provider selection documentation and submit responses prior to the deadline stated in this notice. The ITT documentation including a questionnaire is available through the Atamis (Health Family) portal: <https://health-family.force.com/s/Welcome>. The reference is C153405 and the closing date for completed ITT responses is 12pm, midday on Friday 5th May 2023. There will also be an opportunity to attend a market engagement event via Microsoft Teams at 11.30am on Thursday 20th April 2023. If you would like to participate in this event, please email josselin.canevet@nhs.net by 12pm on Tuesday 18th April 2023. All slides and questions and responses will be made available to all bidders following the event.

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) Estimated value

Value excluding VAT: £1,000,000

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Start date

16 December 2023

End date

15 December 2031

This contract is subject to renewal

No

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: Yes

Description of options

As a result of this procurement exercise an agreement will be established with the successful

Bidders for a period of 8 years with the Commissioner having the option to extend the Contract for up to a further 18 months. It is anticipated that the contract start date will be 16th December 2023 which is 90 days following the expected final NICE guidance; however, this may be subject to change.

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

Lot 5 – One site to cover the NHS England population in the North West of Englan

Lot No

5

II.2.2) Additional CPV code(s)

- 85100000 - Health services

II.2.3) Place of performance

NUTS codes

- UKD - North West (England)

II.2.4) Description of the procurement

The key objectives of the Procurement are to commission Haemophilia ATMP treatment

hubs for patients with haemophilia types A and B to serve the population of England, and to

ensure that:

- the providers of Haemophilia ATMP treatment hubs have the correct qualifications and governance arrangements in place to provide these treatments for the NHS in England, and
- the Commissioner is offering services that are safe and of a high standard whilst fulfilling the Commissioner's public duty to provide services that are cost-effective.

The National Institute for Health and Care Excellence (NICE) will be assessing a number of

ATMPs for haemophilia A and B (see Appendix A). To meet the requirements of the expected

NICE guidance, NHS England is commissioning Haemophilia ATMP treatment hubs for patients with haemophilia types A and B. NHS England is seeking to commission eight of the

18 adult Comprehensive Care Centres (CCCs) in England to become 'haemophilia ATMP treatment hubs'. These hubs will deliver the haemophilia gene therapy ATMPs approved by

NICE with a contract duration of 8 years with the option to extend for up to a further 18 months.

For this ITT, we are only commissioning the Haemophilia ATMP treatment hubs.

Separately,

NHS England will work with the UKHCDO to develop a thorough care pathway detailing the

responsibilities of both the hubs and spokes as well as referral and monitoring guidelines to

manage the care of haemophilia patients undergoing ATMP treatment.

Given the significant amount of preparatory work that needs to be undertaken to deliver a gene therapy service, it is not feasible for commissioners and providers to wait until NICE has

made its recommendations to commence commissioning activity.

Providers are therefore submitting bids to deliver a service 'at risk': it may be the case that

the product does not receive a positive NICE recommendation.

Providers wishing to be considered for the delivery of these services will need to respond to

the provider selection documentation and submit responses prior to the deadline stated in this notice.

The ITT documentation including a questionnaire is available through the Atamis (Health Family) portal: <https://health-family.force.com/s/Welcome>. The reference is C153405 and the closing date for completed ITT responses is 12pm, midday on Friday 5th May 2023.

There will also be an opportunity to attend a market engagement event via Microsoft Teams

at 11.30am on Thursday 20th April 2023. If you would like to participate in this event,

please email josselin.canevet@nhs.net by 12pm on Tuesday 18th April 2023. All slides and questions and responses will be made available to all bidders following the event.

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) Estimated value

Value excluding VAT: £1,000,000

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Start date

16 December 2023

End date

15 December 2031

This contract is subject to renewal

No

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: Yes

Description of options

As a result of this procurement exercise an agreement will be established with the successful

Bidders for a period of 8 years with the Commissioner having the option to extend the Contract for up to a further 18 months. It is anticipated that the contract start date will be 16th December 2023 which is 90 days following the expected final NICE guidance; however, this may be subject to change.

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

Lot 6 – One site to cover the NHS England population in the South East of England

Lot No

6

II.2.2) Additional CPV code(s)

- 85100000 - Health services

II.2.3) Place of performance

NUTS codes

- UKJ - South East (England)

II.2.4) Description of the procurement

The key objectives of the Procurement are to commission Haemophilia ATMP treatment hubs for patients with haemophilia types A and B to serve the population of England, and to

ensure that:

- the providers of Haemophilia ATMP treatment hubs have the correct qualifications and governance arrangements in place to provide these treatments for the NHS in England, and
- the Commissioner is offering services that are safe and of a high standard whilst fulfilling the Commissioner's public duty to provide services that are cost-effective.

The National Institute for Health and Care Excellence (NICE) will be assessing a number of

ATMPs for haemophilia A and B (see Appendix A). To meet the requirements of the expected

NICE guidance, NHS England is commissioning Haemophilia ATMP treatment hubs for patients with haemophilia types A and B. NHS England is seeking to commission eight of the

18 adult Comprehensive Care Centres (CCCs) in England to become 'haemophilia ATMP treatment hubs'. These hubs will deliver the haemophilia gene therapy ATMPs approved by

NICE with a contract duration of 8 years with the option to extend for up to a further 18 months.

For this ITT, we are only commissioning the Haemophilia ATMP treatment hubs.

Separately,

NHS England will work with the UKHCDO to develop a thorough care pathway detailing the

responsibilities of both the hubs and spokes as well as referral and monitoring guidelines to

manage the care of haemophilia patients undergoing ATMP treatment.

Given the significant amount of preparatory work that needs to be undertaken to deliver a gene therapy service, it is not feasible for commissioners and providers to wait until NICE has

made its recommendations to commence commissioning activity.

Providers are therefore submitting bids to deliver a service 'at risk': it may be the case that

the product does not receive a positive NICE recommendation.

Providers wishing to be considered for the delivery of these services will need to respond to

the provider selection documentation and submit responses prior to the deadline stated in this notice.

The ITT documentation including a questionnaire is available through the Atamis (Health Family) portal: <https://health-family.force.com/s/Welcome>. The reference is C153405 and the closing date for completed ITT responses is 12pm, midday on Friday 5th May 2023.

There will also be an opportunity to attend a market engagement event via Microsoft Teams

at 11.30am on Thursday 20th April 2023. If you would like to participate in this event, please

email josselin.canevet@nhs.net by 12pm on Tuesday 18th April 2023. All slides and questions and responses will be made available to all bidders following the event.

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) Estimated value

Value excluding VAT: £1,000,000

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Start date

16 December 2023

End date

15 December 2031

This contract is subject to renewal

No

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: Yes

Description of options

As a result of this procurement exercise an agreement will be established with the successful

Bidders for a period of 8 years with the Commissioner having the option to extend the Contract for up to a further 18 months. It is anticipated that the contract start date will be 16th December 2023 which is 90 days following the expected final NICE guidance; however, this may be subject to change.

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2) Description

II.2.1) Title

Lot 7 - One site to cover the NHS England population in the South West of Englan

Lot No

7

II.2.2) Additional CPV code(s)

- 85100000 - Health services

II.2.3) Place of performance

NUTS codes

- UKK - South West (England)

II.2.4) Description of the procurement

The key objectives of the Procurement are to commission Haemophilia ATMP treatment hubs for patients with haemophilia types A and B to serve the population of England, and to

ensure that:

- the providers of Haemophilia ATMP treatment hubs have the correct qualifications and governance arrangements in place to provide these treatments for the NHS in England, and
- the Commissioner is offering services that are safe and of a high standard whilst fulfilling the Commissioner's public duty to provide services that are cost-effective.

The National Institute for Health and Care Excellence (NICE) will be assessing a number of

ATMPs for haemophilia A and B (see Appendix A). To meet the requirements of the expected

NICE guidance, NHS England is commissioning Haemophilia ATMP treatment hubs for patients with haemophilia types A and B. NHS England is seeking to commission eight of the

18 adult Comprehensive Care Centres (CCCs) in England to become 'haemophilia ATMP treatment hubs'. These hubs will deliver the haemophilia gene therapy ATMPs approved by

NICE with a contract duration of 8 years with the option to extend for up to a further 18 months.

For this ITT, we are only commissioning the Haemophilia ATMP treatment hubs.

Separately,

NHS England will work with the UKHCDO to develop a thorough care pathway detailing the

responsibilities of both the hubs and spokes as well as referral and monitoring guidelines to

manage the care of haemophilia patients undergoing ATMP treatment.

Given the significant amount of preparatory work that needs to be undertaken to deliver a gene therapy service, it is not feasible for commissioners and providers to wait until NICE has

made its recommendations to commence commissioning activity.

Providers are therefore submitting bids to deliver a service 'at risk': it may be the case that

the product does not receive a positive NICE recommendation.

Providers wishing to be considered for the delivery of these services will need to respond to

the provider selection documentation and submit responses prior to the deadline stated in this notice.

The ITT documentation including a questionnaire is available through the Atamis (Health Family) portal: <https://health-family.force.com/s/Welcome>. The reference is C153405 and the closing date for completed ITT responses is 12pm, midday on Friday 5th May 2023.

There will also be an opportunity to attend a market engagement event via Microsoft Teams

at 11.30am on Thursday 20th April 2023. If you would like to participate in this event, please

email josselin.canevet@nhs.net by 12pm on Tuesday 18th April 2023. All slides and questions and responses will be made available to all bidders following the event.

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) Estimated value

Value excluding VAT: £1,000,000

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Start date

16 December 2023

End date

15 December 2031

This contract is subject to renewal

No

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: Yes

Description of options

As a result of this procurement exercise an agreement will be established with the successful Bidders for a period of 8 years with the Commissioner having the option to extend the Contract for up to a further 18 months. It is anticipated that the contract start date will be 16th December 2023 which is 90 days following the expected final NICE guidance; however, this may be subject to change.

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

Section III. Legal, economic, financial and technical information

III.1) Conditions for participation

III.1.1) Suitability to pursue the professional activity, including requirements relating to enrolment on professional or trade registers

List and brief description of conditions

As detailed within the ITT documents

III.1.2) Economic and financial standing

Selection criteria as stated in the procurement documents

III.1.3) Technical and professional ability

Selection criteria as stated in the procurement documents

III.2) Conditions related to the contract

III.2.2) Contract performance conditions

As detailed within the ITT documents

Section IV. Procedure

IV.1) Description

IV.1.1) Type of procedure

Open procedure

IV.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes

IV.2) Administrative information

IV.2.2) Time limit for receipt of tenders or requests to participate

Date

5 May 2023

Local time

12:00pm

IV.2.4) Languages in which tenders or requests to participate may be submitted

English

IV.2.6) Minimum time frame during which the tenderer must maintain the tender

Duration in months: 4 (from the date stated for receipt of tender)

IV.2.7) Conditions for opening of tenders

Date

5 May 2023

Local time

12:00pm

Section VI. Complementary information

VI.1) Information about recurrence

This is a recurrent procurement: No

VI.4) Procedures for review

VI.4.1) Review body

NHS Arden and GEM CSU

Francis Crick House

Northampton

NN3 6BJ

Country

United Kingdom

Internet address

<https://www.ardengemcsu.nhs.uk/>

VI.4.2) Body responsible for mediation procedures

NHS Arden and GEM CSU

Francis Crick House

Northampton

NN3 6BJ

Country

United Kingdom

Internet address

<https://www.ardengemcsu.nhs.uk/>

VI.4.4) Service from which information about the review procedure may be obtained

NHS Arden and GEM CSU

Francis Crick House

Northampton

NN3 6BJ

Country

United Kingdom

Internet address

<https://www.ardengemcsu.nhs.uk/>